Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

NGM Bio Initiates NGM438 Phase 1/1b trial for advanced solid tumors

NGM Biopharmaceuticals, Inc. (NGM Bio) (NASDAQ:NGM) initiated a Phase 1/1b clinical study of its drug candidate NGM438 for the treatment of patients with advanced solid tumors.

This clinical study initiation process brings all three of NGM Bio's wholly-owned myeloid reprogramming product candidates NGM707, a dual ILT2/ILT4 antagonist antibody product candidate, NGM831, an ILT3 antagonist antibody, and NGM438 now into the clinic.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.